Business of Bioanalysis: Understanding ROI in Platform Selection

Watch Dr. Afshin Safavi, BioAgilytix Global CSO discuss why it is important to look at ROI when deciding on what new bioanalytical technologies to invest in – both from a financial perspective, and in the effort it will take to move a drug forward as part of the “Business of Bioanalysis” panel hosted by Bioanalysis Zone.

*Video Produced by Bioanalysis Zone

Share This